Refining the role of combination therapy for the
medical management of benign prostatic hyperplasia
15 Jun 2017
At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).
Related MIMS Drugs